Biofrontera Inc (BFRI)

Currency in USD
1.0950
-0.0150(-1.35%)
Real-time Data·

BFRI Earnings

Latest Release
May 14, 2026
EPS / Forecast
-0.41 / -0.06
Revenue / Forecast
10.08M / --
EPS Revisions
Last 90 days
Release Date
Period End
EPS
/Forecast
Revenue
/Forecast
EPS Surprise %
Revenue Surprise %
Reaction
2026/06--/-0.140--/10.50M----Free Sign Up
2026/03-0.410/-0.06010.08M/---583.33%--Free Sign Up
2025/120.480/0.41017.10M/--+17.07%--Free Sign Up
2025/09-0.620/-0.5706.99M/---8.77%--Free Sign Up
2025/06-0.570/-0.5709.03M/--0%--Free Sign Up
2025/03-0.470/-0.1908.59M/---147.37%--Free Sign Up
2024/12-0.190/-0.20012.56M/14.33M+5%-12.35%Free Sign Up
2024/09-0.980/-1.029.01M/9.71M+3.92%-7.21%Free Sign Up
2024/06-0.050/-1.177.84M/9.26M+95.73%-15.33%Free Sign Up
2024/03-2.88/-0.7707.91M/12.81M-274.03%-38.25%Free Sign Up

All numbers in USD

Biofrontera Inc Earnings Call Summary for Q1/2026

  • Q1 2026 revenue rose 17% YoY to $10.1M; gross margin expanded to 80% from 62%, driven by strategic transaction with Biofrontera AG.
  • Net loss improved to $4.8M ($0.41/share) vs $4.2M ($0.47/share) in Q1 2025; operating expenses increased 10% due to higher SG&A costs.
  • Stock fell 2.9% in premarket despite 68% YTD gain; company faces going concern qualification due to potential liquidity challenges.
  • FY2026 revenue guidance set at $46.76M; expects Q4 2026 profitability with $0.21 EPS after losses in Q2-Q3; FY2027 revenue forecast at $54.7M.
  • FDA approval for Ameluz superficial basal cell carcinoma indication expected by Sept 28, 2026; potential tariff risks on European imports cited.
Last Updated: 2026-05-14, 11:44 a/m
Read Full Transcript

FAQ

What Is Biofrontera's Earnings Per Share (TTM)?

The Biofrontera EPS (TTM) is -1.0200.

When Is The Next Biofrontera Earnings Date?

Biofrontera will release its next earnings report on Aug 07, 2026.

What Is Biofrontera’s Revenue Forecasts For Upcoming Quarters?

Biofrontera’s revenue forecast is 10.50M.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.